Targeted therapy is an important area of treatment for some people with ovarian cancer. Unlike treatments that broadly affect rapidly dividing cells, targeted therapies are designed to act on specific biological pathways involved in cancer growth and survival. Treatment decisions may depend on the type and stage of ovarian cancer, genetic or molecular test results, previous treatments, and overall health. Options can include PARP inhibitors and medicines that target blood vessel formation. Understanding how these therapies work, their possible benefits, limitations, and side effects can help patients discuss available treatment approaches with their oncology team and make informed decisions.
Targeted therapy has become an important part of ovarian cancer treatment for certain patients. These treatments are designed to interfere with specific molecules, genes, or biological processes that may support the growth and spread of cancer cells. Targeted therapies are not appropriate for every type or stage of ovarian cancer, and their use often depends on factors such as tumor characteristics, genetic testing results, previous treatments, and a person's overall health. Understanding the available options can provide useful context when discussing an individualized treatment plan with an oncology team.
One major group of targeted medicines used in ovarian cancer is known as PARP inhibitors. PARP is a protein involved in repairing damaged DNA within cells. Some ovarian cancer cells have changes in genes involved in DNA repair, including BRCA1 or BRCA2. In certain situations, blocking PARP can make it more difficult for these cancer cells to repair DNA damage, which may affect their ability to survive and multiply.
PARP inhibitors may be considered in different treatment settings depending on the characteristics of the cancer and the patient's treatment history. Genetic and molecular testing can play an important role in determining whether this approach may be relevant.
Testing may involve examining inherited genetic changes as well as changes found specifically within the tumor. These results can help healthcare professionals understand the biological features of the cancer and consider which treatment approaches may be suitable.
Another targeted treatment approach involves interfering with angiogenesis, the process through which tumors can develop new blood vessels to obtain oxygen and nutrients. Medicines that affect this pathway may be used in certain ovarian cancer treatment plans, sometimes alongside other therapies or in specific stages of treatment.
Researchers continue to study additional targeted approaches, including treatments directed at molecular pathways, cell signaling processes, and specific characteristics found in tumor cells. Clinical trials may also evaluate new combinations of targeted therapy with chemotherapy, immunotherapy, or other treatment methods.
Treatment planning for ovarian cancer is usually individualized. Healthcare professionals may consider the subtype and stage of cancer, whether the cancer has returned, genetic or biomarker results, previous responses to treatment, and other medical factors. Targeted therapy can offer an additional treatment approach for some patients, but the potential benefits and risks can vary considerably.
Ongoing communication with an oncology team is important for understanding why a particular treatment may or may not be considered. Regular follow-up, appropriate testing, and discussion of possible side effects can support informed decisions throughout the treatment process. This information is provided for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.